[O-34] 一般演題口演セッション34
治療創薬・再生医療２ E

[O-34-3] Satralizumab monotherapy in neuromyelitis optica spectrum disorder: SAkuraStar subgroup analysis

^○Jeffrey L. Bennett¹, Benjamin Greenberg², Anthony Traboulsee³, Lech Szczechowski⁴, Edward Fox⁵, Svitlana Shkrobot⁶, Takashi Yamamura⁷, Yusuke Terada⁸, Yuichi Kawata⁸, H.-christian Von Büdingen⁹, Gaelle Klingelschmitt⁹, Athos Gianella-borradori¹⁰, Brian G. Weinshenker¹¹ (1.University of Colorado School of Medicine, 2.University of Texas Southwestern Medical Center, 3.University of British Columbia, 4.Silesian Centre of Neurology, 5.Central Texas Neurology Consultants, 6.Ternopil State Medical University, 7.National Center of Neurology and Psychiatry, 8.Chugai Pharmaceutical Co., Ltd, Tokyo, 9.F. Hoffmann-La Roche Ltd, 10.Chugai Pharma USA LLC, 11.Mayo Clinic)